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COMMENTARY
How citrullination invaded rheumatoid arthritis
research
Walther J van Venrooij* and Ger JM Pruijn
Abstract
Citrullination and the immune response to citrullinated
proteins have been fundamental for the early
recognition of rheumatoid arthritis by serological tests
and a better understanding of its pathophysiology.
In the first years after the initial publications, the focus
was on the antibodies directed to citrullinated proteins.
It is now realized that citrullinating enzymes and
citrullinated proteins may have important roles in the
maintenance of the inflammatory processes in the
joints. There is also accumulating evidence for a
direct role of citrullination in tissue destruction in
the rheumatoid synovium. Here we will discuss the
development and importance of anti-citrullinated
protein antibodies in rheumatoid arthritis as well as
recent findings implicating citrullination in the
pathophysiology of rheumatoid arthritis.
The first indication that patients with rheumatoid arth-
ritis (RA) produce antibodies to a specific autoantigen
was published in 1964 by two Dutch scientists, Nienhuis
and Mandema. The exact nature of this antigen, the
so-called perinuclear factor, remained unclear for decades.
In 1978, the target of seemingly unrelated RA-specific
autoantibodies (that is, keratin) was identified. Almost 15
years later, Guy Serre’s group convincingly showed that
both antigens were identical to the cytokeratin filament-
aggregating protein filaggrin (reviewed in [1]). Our own
previously published results had shown that the newly
made precursor of filaggrin in cultured buccal mucosa
cells (that is, profilaggrin) did not react with RA antibodies
[2]. This prompted us to consider the possibility that a
post-translational modification of filaggrin, absent on
newly made profilaggrin, was required for the formation
of the antigenic target of these antibodies. Since 1994, we
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have tested several likely modifications using synthetic
peptides. Indeed, citrullination, the enzymatic conversion
of peptidylarginine into peptidylcitrulline, turned out to be
essential to make peptides reactive with RA autoanti-
bodies. We subsequently developed an enzyme-linked
immunosorbent assay with citrullinated peptides and con-
firmed that the anti-peptidylcitrulline activity was specific
for RA [3]. Our further work was directed to the develop-
ment of the CCP2 test, using cyclic citrullinated peptides
(CCPs) selected from random peptide libraries [4].
The discovery of CCP/protein as the most prominent
RA-specific antigen had great impact on RA diagnostics
and our understanding of RA pathophysiology. The fol-
lowing milestones can be noted (see [5] also).
1. After decades of intensive research by many groups,
a specific diagnostic test for RA had finally been
developed. The CCP2 test has a specificity of more
than 95%, is very sensitive (~75%), and is still
considered the gold standard in RA autoantibody
testing. Since 2010, anti-citrullinated protein anti-
bodies (ACPAs) have been included in the new
American College of Rheumatology/European
League Against Rheumatism classification criteria
for RA.
2. Recently, an international reference preparation for
ACPAs was evaluated by the International
Committee for the Standardization of
Autoantibodies in Rheumatic and Related Diseases
[6]. It is available for the scientific community via
the Centers for Disease Control and Prevention
(Atlanta, GA, USA).
3. A positive CCP2 test predicts the development of
RA, often years before clinical confirmation
(reviewed in [5]). It appears that time to RA
diagnosis is shorter in patients with high anti-CCP2
titers at enrollment as compared with those with
low titers [7].
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4. ACPA-positive RA is characterized by a more severe
disease course. Early treatment of ACPA-positive
individuals appears to be very effective.
5. ACPA-negative patients (about 25% of the total RA
population) generally display a much milder course of
disease. About 35% of such ACPA-negative patients
produce anti-carbamylated protein antibodies. Interest-
ingly, the chemical product of carbamylation (that is,
lysine converted to homocitrulline) is structurally very
similar to citrulline [8].
6. Specific human leukocyte antigen (HLA) genes (DRB1
shared epitope (SE) alleles) not only are the most
important genetic risk factor for RA but also are
strongly associated with the production of ACPAs.
7. The best known environmental risk factor for RA,
cigarette smoking, is a risk factor only for ACPA-
positive and not for ACPA-negative RA [9]. There is
increasing evidence that smoking acts as a trigger
for anti-citrulline immunity and does so mainly in
the context of certain HLA genes and certain other
genetic risk factors.
8. ACPAs and citrullinated antigens form immune
complexes which stimulate the inflammatory
process. Continuous production of such immune
complexes ultimately results in the chronic
inflammation, characteristic for RA (Figure 1).
Topical aspects of citrullination in rheumatoid
arthritis
Autoimmunity against citrullinated autoantigens may be
initiated at sites different from the joints. Indeed,
evidence has been presented that citrullinated antigens
may be produced in lungs during smoking or in gums
during infection with bacteria like Porphyromonas gingi-
valis (reviewed in [10]; also, see Figure 1). Nevertheless,
it has been shown that ACPAs accumulate in synovial
fluid of active rheumatic joints as compared with the
corresponding serum and that about 25% of synovial
IgG-expressing B cells are specific for citrullinated
antigens in patients with ACPA-positive RA [11]. These
data suggest that ACPAs at least partially are produced
in the inflamed joints and that joint-specific citrullinated
antigens may diversify and shape the ACPA profile.
Low-avidity ACPAs may be found in both healthy
subjects and patients. However, using longitudinal samples
obtained from individuals prior to disease onset, ACPA
avidity was shown to increase over time until disease
onset, after which no further avidity maturation was ob-
served [12]. These data corroborate the notion that ACPAs
play an important role in the pathogenesis of RA.
ACPAs represent a heterogeneous group of antibodies
recognizing multiple citrullinated peptides and proteins.
It remains to be established whether the subclassification
Figure 1 Citrullination-related immunity and pathophysiology in rheumatoid arthritis. In genetically susceptible individuals, an
environmental factor may initiate a primary inflammation, which can occur in various tissues, and trigger the immune response to citrullinated
proteins (left). The resulting anti-citrullinated protein/peptide antibodies (ACPAs) are distributed through the circulation and may form immune
complexes with citrullinated proteins produced in an inflamed synovium, thereby boosting the inflammatory process. This will be associated with
the infiltration and activation of neutrophils, macrophages, and lymphocytes; cell death; extracellular DNA trap formation; the activation and release of
peptidylarginine deiminases (PADs); de novo citrullination; and diversification of the ACPA response. Besides the common inflammation-associated
mediators of tissue destruction (not shown), ACPAs and PADs can be directly involved in these processes. HLA, human leukocyte antigen.
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based upon ACPA fine-specificity profiles is clinically
meaningful.
In the last few years, it also became clear that citrullina-
tion may be instrumental to the tissue destruction pro-
cesses in the synovium. ACPAs were shown to bind to
osteoclast surfaces and to induce osteoclast differentiation
and subsequent bone resorption [13]. This may explain
why ACPA is strongly associated with bone erosion. It is
tempting to speculate that the degradation of cartilage is
mediated by similar mechanisms. Alternatively, this may
be induced by citrullinating enzymes (peptidylarginine dei-
minases, or PADs), which may citrullinate proteins at the
surface of cartilage, inducing their rapid degradation and
destabilization of the cartilage.
Next to the antibodies, the citrullination of proteins in
the synovium may lead to changes in important physio-
logical processes. Citrullinated fibrinogen and citrullinated
collagen type II are more immunogenic and arthritogenic
in mouse models of arthritis, and citrullinated fibrinogen
activates macrophages more than unmodified fibrinogen
[10]. Recently, citrullination of fibronectin was shown to
alter synovial fibroblast behavior [14]. Sokolove and col-
leagues [15] found that fragments of citrullinated proteins
can bind to ACPAs and cause activation of macrophages
and antigen-presenting cells. Ling and colleagues [16]
showed that cell surface calreticulin interacts with the SE
to transduce innate immune signals. Citrullination of cal-
reticulin, an abundant process in inflamed synovial tissue,
appeared to enhance its affinity for the SE, thus increasing
its signaling potency significantly [16]. Interestingly, auto-
citrullination of PAD4 has been reported to inactivate this
enzyme and to enhance its recognition by anti-PAD4 RA
sera [17]. Although not all of these data have been con-
firmed yet by other groups, they strongly suggest that, in
addition to ACPA production, protein citrullination can
affect the pathophysiology of RA at several levels.
A very interesting phenomenon that links citrullination
to inflammation and autoimmunity is the formation of
extracellular DNA traps, which is part of the innate
immune response [18]. Several inflammatory cells
externalize a meshwork of chromatin fibers, containing
citrullinated histones, decorated with granule-derived
(antimicrobial) proteins. Extracellular trap formation is
dependent on citrullination, and proteins associated with
these traps may serve as self-antigens [19]. The potential
relationship between the anti-citrullinated protein
response in RA and citrullination in extracellular traps
remains to be investigated.
It is evident by now that the study of citrullination,
ACPAs, and citrullinating enzymes becomes more and
more important to understand the pathophysiology of RA.
It is likely that other modifications of cellular proteins
may be intrinsic factors of other autoimmune diseases.
Future studies have to prove this idea.
Abbreviations
ACPA: Anti-citrullinated protein/peptide antibody; CCP: Cyclic citrullinated
peptide; HLA: Human leukocyte antigen; Ig: Immunoglobulin;
PAD: Peptidylarginine deiminase; RA: Rheumatoid arthritis; SE: Shared
epitope.
Competing interests
WJvV and GJMP are consultants to Axis-Shield Diagnostics Ltd (Dundee,
Scotland) and Euro-Diagnostica AB (Malmö, Sweden).
Published:
References
1. Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, Serre
G: The cytokeratin filament-aggregating protein filaggrin is the target of
the so-called "antikeratin antibodies," autoantibodies specific for
rheumatoid arthritis. J Clin Invest 1993, 92:1387–1393.
2. Hoet RM, Boerbooms AM, Arends M, Ruiter DJ, van Venrooij WJ:
Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis:
colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis
1991, 50:611–618.
3. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van
Venrooij WJ: Citrulline is an essential constituent of antigenic
determinants recognized by rheumatoid arthritis-specific autoantibodies.
J Clin Invest 1998, 101:273–281.
4. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM,
Breedveld FC, van Venrooij WJ: The diagnostic properties of rheumatoid
arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis
Rheum 2000, 43:155–163.
5. van Venrooij WJ, van Beers JJ, Pruijn GJ: Anti-CCP antibodies: the past, the
present and the future. Nat Rev Rheumatol 2011, 7:391–398.
6. Bizzaro N, Pregnolato F, van Boekel MA, Villalta D, Tozzoli R, Tonutti E,
Antico A, Borghi MO, Wiik A, Meroni PL: Preliminary evaluation of the first
international reference preparation for anticitrullinated peptide
antibodies. Ann Rheum Dis 2012, 71:1388–1392.
7. Bizzaro N, Bartoloni E, Morozzi G, Manganelli S, Riccieri V, Sabatini P, Filippini
M, Tampoia M, Afeltra A, Sebastiani G, Alpini C, Bini V, Bistoni O, Alunno A,
Gerli R, the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni
(FIRMA Group): Anti-cyclic citrullinated peptide antibody titer predicts
time to rheumatoid arthritis onset in patients with undifferentiated
arthritis: results from a 2-year prospective study. Arthritis Res Ther 2013,
15:R16.
8. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen
PA, Levarht NE, van der Helm-van Mil AH, Cerami A, Huizinga TW, Toes RE,
Trouw LA: Autoantibodies recognizing carbamylated proteins are present
in sera of patients with rheumatoid arthritis and predict joint damage.
Proc Natl Acad Sci U S A 2011, 108:17372–17377.
9. Klareskog L, Malmstrom V, Lundberg K, Padyukov L, Alfredsson L: Smoking,
citrullination and genetic variability in the immunopathogenesis of
rheumatoid arthritis. Sem Immunol 2011, 23:92–98.
10. Quirke AM, Fisher BA, Kinloch AJ, Venables PJ: Citrullination of
autoantigens: upstream of TNFalpha in the pathogenesis of rheumatoid
arthritis. FEBS Lett 2011, 585:3681–3688.
11. Amara K, Steen J, Murray F, Morbach H, Fernandez-Rodriguez BM, Joshua V,
Engström M, Snir O, Israelsson L, Catrina AI, Wardemann H, Corti D, Meffre E,
Klareskog L, Malmström V: Monoclonal IgG antibodies generated from
joint-derived B cells of RA patients have a strong bias toward citrulli-
nated autoantigen recognition. J Exp Med 2013, 210:445–455.
12. Suwannalai P, van de Stadt LA, Radner H, Steiner G, El-Gabalawy HS, Zijde
CM, van Tol MJ, van Schaardenburg D, Huizinga TW, Toes RE, Trouw LA:
Avidity maturation of anti-citrullinated protein antibodies in rheumatoid
arthritis. Arthritis Rheum 2012, 64:1323–1328.
Note: This article is part of the collection Research through the
eyes of pioneers. Other articles in this series can be found at
http://arthritis-research.com/series/pioneers.




13. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ,
Baum W, Nimmerjahn F, Szarka E, Sarmay G, Krumbholz G, Neumann E, Toes
R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G: Induction of
osteoclastogenesis and bone loss by human autoantibodies against
citrullinated vimentin. J Clin Invest 2012, 122:1791–1802.
14. Shelef MA, Bennin DA, Mosher DF, Huttenlocher A: Citrullination of
fibronectin modulates synovial fibroblast behavior. Arthritis Res Ther 2012,
14:R240.
15. Sokolove J, Zhao X, Chandra PE, Robinson WH: Immune complexes
containing citrullinated fibrinogen costimulate macrophages via Toll-like
receptor 4 and Fcgamma receptor. Arthritis Rheum 2011, 63:53–62.
16. Ling S, Cline EN, Haug TS, Fox DA, Holoshitz J: Citrullinated calreticulin
potentiates rheumatoid arthritis shared epitope signaling. Arthritis Rheum
2013, 65:618–626.
17. Andrade F, Darrah E, Gucek M, Cole RN, Rosen A, Zhu X:
Autocitrullination of human peptidyl arginine deiminase type 4
regulates protein citrullination during cell activation. Arthritis Rheum
2010, 62:1630–1640.
18. Simon D, Simon HU, Yousefi S: Extracellular DNA traps in allergic,
infectious, and autoimmune diseases. Allergy 2013, 68:409–416.
19. Knight JS, Carmona-Rivera C, Kaplan MJ: Proteins derived from neutrophil
extracellular traps may serve as self-antigens and mediate organ
damage in autoimmune diseases. Front Immunol 2012, 3:380.
Cite this article as: van Venrooij and Pruijn: How citrullination invaded
rheumatoid arthritis research. Arthritis Research & Therapy
van Venrooij and Pruijn Arthritis Research & Therapy Page 5 of 5
10.1186/ar4458
2014, 16:103
2014, 16:103
http://arthritis-research.com/content/16/1/103
